Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (Weighted Average) (2023 - 2025)

Contineum Therapeutics has reported Shares Outstanding (Weighted Average) over the past 3 years, most recently at $28.1 million for Q3 2025.

  • Quarterly results put Shares Outstanding (Weighted Average) at $28.1 million for Q3 2025, up 63.63% from a year ago — trailing twelve months through Sep 2025 was $28.1 million (up 63.63% YoY), and the annual figure for FY2024 was $19.4 million, up 736.66%.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $28.1 million at Contineum Therapeutics, up from $25.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CTNM hit a ceiling of $28.1 million in Q3 2025 and a floor of $2.3 million in Q1 2023.
  • Median Shares Outstanding (Weighted Average) over the past 3 years was $12.9 million (2024), compared with a mean of $12.8 million.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 4.02% in 2024 and later soared 991.95% in 2025.
  • Contineum Therapeutics' Shares Outstanding (Weighted Average) stood at $2.3 million in 2023, then soared by 736.66% to $19.4 million in 2024, then surged by 45.28% to $28.1 million in 2025.
  • The last three reported values for Shares Outstanding (Weighted Average) were $28.1 million (Q3 2025), $25.9 million (Q2 2025), and $25.9 million (Q1 2025) per Business Quant data.